Eyebright Medical(SH:688050) Zhong Guo Jing Ji Wang·2026-02-26 02:40Core Viewpoint - Aibo Medical (688050.SH) announced the acquisition of 68.31% equity in Demai United (Chongqing) Medical Technology Co., Ltd. for a total consideration of RMB 683 million, which will enhance its position in the sports medicine sector and integrate Demai Medical as a subsidiary [1][2]. Group 1: Acquisition Details - The acquisition will be financed through a combination of merger loans and the company's own funds, with the transaction price set at RMB 68,300.46 million [1]. - Following the payment of the first installment, the equity transfer will be completed, granting Aibo Medical full rights as a shareholder of Demai Medical [1]. - Demai Medical is recognized as a leading enterprise in sports medicine in China, holding 276 patents and classified as a national high-tech enterprise [1]. Group 2: Valuation and Financials - A valuation report by Beijing Zhongfeng Asset Appraisal Co., Ltd. assessed Demai Medical's total equity value at RMB 107,429.74 million, with a net asset book value of RMB 24,234.48 million, resulting in an appraisal increment of RMB 83,195.26 million and a value increase rate of 343.29% [2]. - Key financial data for Demai Medical includes total assets of RMB 42,533.86 million and total liabilities of RMB 16,209.20 million as of December 31, 2025, with a projected net profit of RMB 3,501.67 million [3]. Group 3: Company Background - Aibo Medical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 29, 2020, raising a total of RMB 882 million, with a net amount of RMB 804 million after deducting issuance costs [4]. - The company plans to utilize the raised funds for expanding production capacity, developing high-end medical equipment, and enhancing its marketing network [4].